NCTId,BriefTitle,Condition,LeadSponsorName,OverallStatus,Phase,InterventionType,CompletionDate,InterventionName
NCT02137382,"A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis,Abbott,Completed,Phase 3,"['Drug', 'Drug']",August 2014,"['Creon®', 'Creon N']"
NCT03924947,"A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis",Cystic Fibrosis,AbbVie,"Active, not recruiting",Phase 4,Drug,"July 28, 2022",Pancrelipase
NCT01641822,Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF,Cystic Fibrosis,Gilead Sciences,Completed,Phase 3,"['Drug', 'Drug', 'Drug']",January 2015,"['AZLI', 'Placebo to match AZLI', 'Tobramycin inhalation solution']"
NCT00757237,Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa,Cystic Fibrosis,Gilead Sciences,Completed,Phase 3,"['Drug', 'Drug']",November 2010,"['Aztreonam for Inhalation Solution (AZLI)', 'Tobramycin Inhalation Solution (TIS)']"
NCT00128492,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA),Cystic Fibrosis,Gilead Sciences,Completed,Phase 3,Drug,January 2009,AZLI 75 mg two times a day (BID)/ three times a day (TID)
NCT00112359,International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Cystic Fibrosis,Gilead Sciences,Completed,Phase 3,"['Drug', 'Drug']",April 2007,"['AZLI 75 mg three times a day (TID)', 'Placebo three times a day (TID)']"
NCT00104520,Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa,Cystic Fibrosis,Gilead Sciences,Completed,Phase 3,"['Drug', 'Drug']",September 2006,"['AZLI 75 mg two times a day (BID)/three times a day (TID)', 'Placebo two times a day (BID)/three times a day (TID)']"
NCT00625612,Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease,Cystic Fibrosis,Merck Sharp & Dohme LLC,Completed,Phase 3,"['Drug', 'Drug']",October 2010,"['Denufosol Tetrasodium (INS37217) Inhalation Solution', 'Placebo']"
NCT00357279,Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease,Cystic Fibrosis,Merck Sharp & Dohme LLC,Completed,Phase 3,"['Drug', 'Drug']",September 2008,"['denufosol tetrasodium (INS37217) Inhalation Solution', 'Placebo - 0.9% w/v sodium chloride solution']"
NCT05331183,Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Not yet recruiting,Phase 3,"['Drug', 'Drug']",March 2025,"['ELX/TEZ/IVA', 'IVA']"
NCT05274269,Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Recruiting,Phase 3,"['Drug', 'Drug', 'Other', 'Other']",May 2023,"['ELX/TEZ/IVA', 'IVA', 'Placebo (matched to ELX/TEZ/IVA)', 'Placebo (matched to IVA)']"
NCT05153317,Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Enrolling by invitation,Phase 3,"['Drug', 'Drug']",April 2026,"['ELX/TEZ/IVA', 'IVA']"
NCT05111145,A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Enrolling by invitation,Phase 3,"['Drug', 'Drug']",October 2023,"['ELX/TEZ/IVA', 'IVA']"
NCT05076149,"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Recruiting,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']",February 2024,"['VX-121/TEZ/D-IVA', 'ELX/TEZ/IVA', 'IVA', 'Placebo (matched to VX-121/TEZ/D-IVA)', 'Placebo (matched to ELX/TEZ/IVA)', 'Placebo (matched to IVA)']"
NCT05033080,A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Recruiting,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug', 'Drug']",January 2024,"['VX-121/TEZ/D-IVA', 'ELX/TEZ/IVA', 'IVA', 'Placebo (matched to VX-121/TEZ/D-IVA)', 'Placebo (matched to ELX/TEZ/IVA)', 'Placebo (matched to IVA)']"
NCT04969224,A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Subjects With Cystic Fibrosis (CF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",September 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04599465,A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",June 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04545515,A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Subjects 6 Years and Older and F/MF Genotypes,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",April 2023,"['ELX/TEZ/IVA', 'IVA']"
NCT04537793,Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",June 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04362761,A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",June 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04353817,A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Other', 'Other']","May 17, 2021","['ELX/TEZ/IVA', 'IVA', 'Placebo', 'Placebo']"
NCT04235140,Long-term Safety of Lumacaftor/Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,Drug,February 2024,LUM/IVA
NCT04183790,Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",April 2024,"['ELX/TEZ/IVA', 'IVA']"
NCT04105972,"A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']","July 24, 2020","['ELX/TEZ/IVA', 'TEZ/IVA', 'IVA']"
NCT04058366,Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",August 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT04058353,A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']","June 12, 2020","['ELX/TEZ/IVA', 'IVA', 'TEZ/IVA']"
NCT04043806,A Study Evaluating the Long-term Safety of VX-445 Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",May 2022,"['ELX/TEZ/IVA', 'IVA']"
NCT03691779,Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']","August 7, 2020","['ELX/TEZ/IVA', 'IVA']"
NCT03601637,"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']","October 29, 2021","['LUM', 'IVA']"
NCT03559062,A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","December 21, 2018","['TEZ/IVA', 'IVA', 'Placebo', 'Placebo']"
NCT03537651,A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",September 2022,"['TEZ/IVA', 'IVA']"
NCT03525574,A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",January 2023,"['VX-445', 'TEZ', 'IVA', 'IVA']"
NCT03525548,A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","December 28, 2018","['VX-445/TEZ/IVA', 'TEZ/IVA', 'IVA', 'Placebo', 'Placebo']"
NCT03525444,A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']","April 24, 2019","['VX-445/TEZ/IVA', 'IVA', 'Placebo']"
NCT03460990,A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug', 'Drug']","October 8, 2018","['VX-659/TEZ/IVA', 'TEZ/IVA', 'IVA', 'Placebo', 'Placebo']"
NCT03447249,A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']","February 5, 2019","['VX-659/TEZ/IVA', 'IVA', 'Placebo']"
NCT03277196,A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Enrolling by invitation,Phase 3,Drug,"July 3, 2024",Ivacaftor
NCT03150719,"A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","August 9, 2018","['Tezacaftor/Ivacaftor', 'Ivacaftor', 'Placebo', 'Placebo']"
NCT03125395,"A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,Drug,"July 17, 2019",LUM/IVA
NCT03068312,A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']","December 18, 2018","['Ivacaftor', 'Placebo']"
NCT02953314,"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']",September 2018,"['TEZ', 'TEZ/IVA', 'IVA']"
NCT02875366,"A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 4,"['Drug', 'Drug']",October 2017,"['LUM/IVA', 'Placebo']"
NCT02797132,"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,Drug,September 2017,LUM/IVA
NCT02725567,"A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,Drug,July 2022,ivacaftor
NCT02565914,A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,"Active, not recruiting",Phase 3,"['Drug', 'Drug']",March 2023,"['TEZ/IVA', 'IVA']"
NCT02544451,Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",April 2020,"['LUM/IVA', 'LUM/IVA']"
NCT02516410,"A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","June 7, 2016","['VX-661 plus ivacaftor combination', 'Ivacaftor', 'Placebo (matched to VX-661 plus ivacaftor combination)', 'Placebo (matched to ivacaftor)']"
NCT02514473,"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']",September 2016,"['VX-809', 'Placebo', 'VX-770']"
NCT02412111,"A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",September 2017,"['Ivacaftor', 'Tezacaftor/Ivacaftor']"
NCT02392234,"A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']",February 2017,"['VX-661/Ivacaftor', 'Ivacaftor', 'Placebo matched to VX-661/ ivacaftor', 'Placebo matched to Ivacaftor']"
NCT02347657,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug', 'Drug']","January 20, 2017","['VX-661 Plus Ivacaftor Combination', 'Ivacaftor', 'VX-661 Plus Ivacaftor Combination Placebo', 'Ivacaftor placebo']"
NCT01946412,Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,Drug,December 2015,Ivacaftor
NCT01897233,"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation",Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",October 2015,"['Lumacaftor', 'Ivacaftor']"
NCT01707290,Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,Drug,April 2016,Ivacaftor
NCT01705145,Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,Drug,March 2014,Ivacaftor
NCT01614470,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",October 2013,"['Ivacaftor', 'Placebo']"
NCT01614457,Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT),Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",October 2013,"['Ivacaftor', 'Placebo']"
NCT01117012,Rollover Study of VX-770 in Cystic Fibrosis Subjects,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,Drug,May 2014,Ivacaftor
NCT00909727,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",April 2011,"['Ivacaftor', 'Placebo']"
NCT00909532,Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation,Cystic Fibrosis,Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",November 2012,"['Ivacaftor', 'Placebo']"
NCT01807949,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']",April 2014,"['Placebo', 'Lumacaftor Plus Ivacaftor Combination', 'Ivacaftor']"
NCT01807923,A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation,"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug', 'Drug']",April 2014,"['Lumacaftor Plus Ivacaftor Combination', 'Ivacaftor', 'Placebo']"
NCT01931839,A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis,"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation",Vertex Pharmaceuticals Incorporated,Completed,Phase 3,"['Drug', 'Drug']",April 2016,"['Lumacaftor Plus Ivacaftor Combination', 'Ivacaftor']"
